Literature DB >> 12041679

Imatinib mesylate (Gleevec) in the treatment of 2 patients with Philadelphia-positive ALL relapsing after allogeneic stem cell transplantation.

Keiji Sugimoto, Michiaki Mikoshiba, Kazuteru Ohashi, Hideki Akiyama, Hisashi Sakamaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12041679     DOI： 10.1007/bf02982139

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  10 in total

1.  Treatment of Relapsing Ph+ Acute Lymphoblastic Leukemia with Donor Leukocyte Infusion Followed by Quantitative Monitoring of Residual Disease.

Authors:  N Kono; K Ohashi; Y Okuyama; S Mori; K Hiruma; H Akiyama; T Fukui; K Osumi; H Sakamaki
Journal:  Hematology       Date:  2001       Impact factor: 2.269

Review 2.  Treatment of acute lymphoblastic leukemia.

Authors:  D Hoelzer
Journal:  Semin Hematol       Date:  1994-01       Impact factor: 3.851

3.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Authors:  R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  Donor leukocyte infusions in acute lymphocytic leukemia.

Authors:  R H Collins; S Goldstein; S Giralt; J Levine; D Porter; W Drobyski; J Barrett; M Johnson; A Kirk; M Horowitz; P Parker
Journal:  Bone Marrow Transplant       Date:  2000-09       Impact factor: 5.483

5.  Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  J Sierra; J Radich; J A Hansen; P J Martin; E W Petersdorf; J Bjerke; E Bryant; R A Nash; J E Sanders; R Storb; K M Sullivan; F R Appelbaum; C Anasetti
Journal:  Blood       Date:  1997-08-15       Impact factor: 22.113

6.  Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.

Authors:  B Wassmann; S A Klein; U Scheuring; H Pfeifer; H Martin; H Gschaidmeier; D Hoelzer; O G Ottmann
Journal:  Bone Marrow Transplant       Date:  2001-10       Impact factor: 5.483

7.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

8.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Authors:  B J Druker; C L Sawyers; H Kantarjian; D J Resta; S F Reese; J M Ford; R Capdeville; M Talpaz
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

9.  Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG).

Authors:  M Tanimoto; S Miyawaki; T Ino; T Kyo; H Sakamaki; T Naoe; A Hiraoka; N Asou; T Ohshima; K Tsubaki; K Kuriyama; T Ueda; S Minamil; K Okabe; H Saito; H Murakami; M Hirano; H Dohy; Y Onozawa; H Suzuki; R Ohno
Journal:  Int J Hematol       Date:  1998-12       Impact factor: 2.490

10.  Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group.

Authors:  T Ueda; S Miyawaki; N Asou; Y Kuraishi; A Hiraoka; K Kuriyama; S Minami; T Ohshima; T Ino; J Tamura; A Kanamaru; K Nishikawa; M Tanimoto; H Oh; K Saito; K Nagata; T Naoe; O Yamada; Y Urasaki; T Sakura; R Ohno
Journal:  Int J Hematol       Date:  1998-10       Impact factor: 2.490
  10 in total
  1 in total

1.  Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation.

Authors:  Toshiaki Yujiri; Yutaka Sato; Yukio Tanizawa
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.